CureVac Settles Patent Dispute with Pfizer/BioNTech

CureVac N.V., a German biotech company, has resolved a patent litigation with Pfizer and BioNTech concerning mRNA-based COVID-19 vaccines. The agreement includes a $740 million payment to CureVac and its partner, GSK, alongside royalties on future U.S. vaccine sales. Additionally, CureVac will receive $50 million from GSK for certain U.S. product royalties.

Under the settlement terms, CureVac will grant a non-exclusive license to BioNTech and Pfizer for the manufacture and sale of mRNA COVID-19 and influenza products in the U.S. This license will extend worldwide upon the completion of BioNTech's acquisition of CureVac.

The acquisition, announced in June 2025, awaits regulatory approval but is expected to proceed without changes. This resolution signifies a strategic collaboration between leading biopharmaceutical firms in the evolving mRNA sector.